ClinicalTrials.gg
Not yet recruitingNCT06789094ASCAUpdated Jan 23, 2025

Validating the Ain Shams Cognitive Assessment Tool

An observational study in Mild Cognitive Impairment (MCI) and Dementia, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Ain Shams University · Observational

How we know · 2 judgments

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Cognitive Dysfunction with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Egypt.

Planned enrollment
5th of 11
100 · median 100
Started
2025
with 2 others
Observational
11 of 29
3 open now
Registered
23rd of 29
by date
Lead sponsor
3 of 29
Ain Shams University

Among the 29 studies in Cognitive Dysfunction with a site in Egypt, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 23rd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

7 of the 29 studies in Cognitive Dysfunction with a site in Egypt are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Cognitive Dysfunction with a site in Egypt, or all of them as a file.
02

Study summary

The diagnosis of cognitive impairment, including dementia and mild cognitive impairment (MCI), is crucial for timely intervention and management. Various screening tools are available for assessing cognitive function, among which the Mini-Mental State Examination (MMSE), the Addenbrooke's Cognitive Examination (ACE), and the Montreal Cognitive Assessment (MoCA) are widely used. However, the recently developed Ain Shams University Cognitive Assessment (ASCA) has shown promise in detecting early cognitive decline. This study aims to assess the performance of ASCA in diagnosing cognitive impairment against DSM5 criteria.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Dementia

Keywords

  • Mild cognitive impairment
  • Dementia
  • cognitive assessment
  • Arabic cognitive assessment tools
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Community dwelling elderly participants (caregivers of inpatients, attendants of primary care , elderly clubs and other community gatherings).

Eligibility criteria

Inclusion Criteria: older adult participants 60 years old and above who are native Arabic speakers

-

Exclusion Criteria:

  • severe dementia, delirium, major mental disorders, aphasia, and those with severe visual or hearing impairment that interfere with the assessment.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dementia

    participants \>60 years with Dementia diagnosed by DSM-5 criteria

    Other: Ain Shams University Cognitive Assessment (ASCA) tool

  • Mild cognitive impairment

    participants \>60 years with Mild cognitive impairment (MCI) diagnosed by DSM-5 criteria

    Other: Ain Shams University Cognitive Assessment (ASCA) tool

  • control

    euthymic healthy community dwelling adult participants of various socioeconomic and educational status.

    Other: Ain Shams University Cognitive Assessment (ASCA) tool

Interventions

  • OtherAin Shams University Cognitive Assessment (ASCA) tool

    The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.

    Also known as: Patient Health Questionnaire 9, activity of daily living questionnaire

06

What researchers measure

Primary outcomes

  1. ASCA cut off points

    obtain cut-off scores for diagnosing mild cognitive impairment (MCI) and dementia using the Ain Shams Cognitive Assessment

    Time frame: 4 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for May 2025, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 23, 2025
StartEst.
Feb 1, 2025
Primary completionEst.
May 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06789094
Responsible party
Doha Rasheedy (Professor of Geriatrics and Gerontology, Ain Shams University) — Principal investigator
First posted
Jan 23, 2025
Start date
Feb 1, 2025 (estimated)
Primary completion
May 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Jan 23, 2025

Study contacts

Doha Rasheedy, Professor
Contact
doharasheedy@med.asu.edu.eg
01001193544 ext. 202

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion